CBD may reduce COVID-19-related lung inflammation

CBD may reduce COVID-19-related lung inflammation

Since early 2020, Europe has been undergoing a totally unprecedented situation... A war against an invisible enemy: COVID-19. After several months' containment before the summer, European leaders are looking for solutions to mitigate this 2nd wave. Last night, French President Emmanuel Macronchose to recontain his entire country for a minimum of 4 weeks. As the number of people affected grows daily, as does the number of deaths, scientists around the world have begun to investigate whether the CBD cannabis plant could reduce COVID-19 lung inflammation. We'll take a closer look in the next few lines.

CBD helps rebalance apelin levels

The idea of CBD's effectiveness against COVID-19 took shape a few days ago. American researchers from the Medical College of Georgia (MCG) at Augusta University have discovered that cannabidiol helps reduce lung damage while preventing respiratory distress syndrome. A mechanism linked to apelin levels. These results were published on October 15 in the Journal of Cellular and Molecular Medicine.

What is apeline?

Apelin is "a protective peptide produced by cells of the blood, brain, heart, lungs and adipose tissue". American scientists are unanimous in their belief that apelin plays a role in regulating blood pressure, thereby reducing inflammation. Indeed, tests have shown that CBD can increase levels of this molecule, making the cytokine storm that causes violent inflammatory reactions damaging the lungs and other organs less progressive. Patients suffering fatal respiratory distress generally had apelin levels close to zero.

As you may have guessed, the low levels are caused by the cytokine shock engendered by the Covid-19 infection... All of which forces the immune system to overreact and thus provoke inflammation. In addition, the study reports that apelin levels increase 20-fold after CBD treatment, allowing a return to "normal" levels. normal " - said Dr. Jack Yu, Medical Scientist and Head of Pediatric Plastic Surgery at MCG, on the first apparent link between CBD and apelin. Cannabidiol could indeed reduce COVID-19-related lung inflammation.

Need for further studies and trials

Although this research seems to lead to gradual optimism, the authors remain cautious and point out that more work is needed. The initial findings are based on an observational study and therefore need to be confirmed.

"It's an association but we don't yet know what's causal, but it's a very good indicator of disease," explained Dr Babak Baban, immunologist and author of the study.

Thus, it will be essential to conduct trials before including CBD as part of a treatment process for Covid-19.

To be continued...

 

 

Perhaps you have more specific questions about CBD and its uses?

Through our articles, we try to answer you:

 

newsletter

Receive our latest news, information and promotions on our products.

One comment on "CBD could reduce COVID-19-related lung inflammation"

  1. Jimmy Pierrot said:

    Hello,

    Swiss and European legislation prohibits any company from selling a concentrated CBD extract as sublingual (NOVEL FOOD regulations governing new foods marketed after 1997: Concentrated hemp extract). Products presented as CBD oils that can be taken by mouth are illegal.

    The only possible classification is "cosmetic product" for cutaneous application. On the other hand, we know that 90% of our customers who have been using our CBD oils for nearly 4 years do so by mouth, although we cannot recommend this.

    This is why we carry out so-called "food grade" analyses of our CBD oils two or three times a year (for pesticides, herbicides, heavy metals, pollutants and bacteriological proliferation) so that, even if we can't recommend it, customers who take them by mouth can do so in complete safety.

    We also carry out THC/CBD analyses on each production batch.

    If you have any questions, please do not hesitate to contact us by phone.

    Sincerely,

Leave a comment

Your email address will not be published. Required fields are marked with *.

This site uses cookies to provide you with a better browsing experience. By browsing this site, you agree to our use of cookies.